- Historic Pharmaceutical Pricing Deal: The U.S. and U.K. have reached an agreement in principle to address pharmaceutical trade imbalances, increasing the net price the U.K. pays for new medicines by 25% and reversing a decade-long decline in NHS expenditures on innovative medicines.
- Economic and Investment Benefits: This agreement aims to strengthen the pharmaceutical industry in both countries, fostering investment, innovation, and job creation while ensuring that American citizens no longer bear the highest drug costs globally.
- Tariff Exemptions and Regulatory Commitments: In exchange for the U.K.’s commitments, the U.S. will exempt U.K.-origin pharmaceuticals from Section 232 tariffs and not target U.K. pricing practices in future investigations, enhancing access to new pharmaceutical breakthroughs for U.K. citizens.
Source ustr.gov
Latest Posts in "United Kingdom"
- UK VAT Rules on Online Prize Draws Face Scrutiny Amid New Voluntary Code and Industry Growth
- How UK Businesses Accidentally Trigger US State Sales Tax Through Ecommerce and Economic Nexus
- Director Liable for VAT Fraud and PAYE/NIC on Withdrawals: Ellis & Anor v HMRC (2026)
- UK VAT Gap Rises to £11.9bn in 2024–25, HMRC Reports 6.5% Shortfall
- Luzha v HMRC: VAT Late Submission Penalties Upheld, No Reasonable Excuse Found, Appeal Dismissed
